The effects of statin use on the development of tuberculosis among patients with diabetes mellitus

Kang, Young Ae; Choi, Nam-Kyong; Seong, Jong-Mi; Heo, Eun Young; Koo, Bo Kyung; Hwang, Seung Sik; Park, B. J.; Yim, Jae Joon; Lee, C. H.

doi:10.5588/ijtld.13.0854

Cited by 36 publications

(53 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are significant differences in the study design and results between our study and Kang et al 's study conducted in South Korea. In that study, it was found that the use of statins in patients with diabetes did not affect the risk of active TB (adjusted HR 0.98; 95% CI 0.89 to 1.07) 28. We believe that this finding cannot be applied to the general population because diabetes is associated with a threefold higher risk of TB, as determined by a meta-analysis 29.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort

Lai

Lee

et al. 2016

Thorax

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

“…Second, we observed that the protective effects of statins are mainly observed in current or chronic users but not in past users. Unfortunately, the different types of statin users were combined in Kang et al 's work 28. Thus, the protective effect of statins might have been overlooked.…”

Section: Discussionmentioning

confidence: 99%

Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort

Lai

Lee

et al. 2016

Thorax

View full text Add to dashboard Cite

show abstract

“…107 As adjunctive therapy in murine TB, statins shorten the time to culture negativity by 1 month, reduce tissue pathology, decrease the proportion of culturepositive relapse cases and enhance bacterial killing. [108][109] Statin usage by newly diagnosed type-2 diabetics did however, not prevent development of TB, 110 and further studies are required.…”

Section: Cholesterol-lowering Drugsmentioning

confidence: 99%

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

Tiberi

Plessis

Walzl

et al. 2018

The Lancet Infectious Diseases

308

275

View full text Add to dashboard Cite

Tuberculosis (TB) remains the top killer from an infectious globally causing an estimated 1.674.000 million deaths worldwide. In 2016, WHO estimates 600.000 cases of rifampicin-resistant TB of which 490.000 had multidrug-resistant (MDR) and less than half of them survive after receiving currently recommended WHO treatment regimens, illustrating weaknesses in current treatment approaches. We review progress and advances in the development of new and repurposed TB drugs, treatment trials and host-directed therapies. Updates are provided on phase 3 trials of the new compounds bedaquiline, delamanid, pretomanid; phase 2 trials of sutezolid, SQ-109, LCB01-0371, PBTZ-169; and five new drugs in phase 1 development. Approved or repurposed drugs undergoing further testing are rifampicin, rifapentine, clofazimine, and linezolid. Update on ongoing clinical trials, which aim to shorten TB treatment and improve treatment outcome is given. Several new or repurposed antimicrobial drugs are in advanced trial stages for MDR-TB, and five antimicrobial drug candidates are in phase 1 (Q203, TBI-166, OPC-167832, GSK 070, TBA-7371) and 5 in pre-clinical studies. Specific issues of safety and toxicity; drug-drug interactions; Therapeutic Drug Monitoring are reviewed. A wide range of candidate host-directed therapies (HDTs) and immune-based treatments are being investigated to accelerate the eradication of M.tb infection and for use as adjunctive therapy in shortening duration of treatment, preventing permanent lung injury and improving treatment outcomes of MDR-TB. Ongoing clinical trials of HDTs for TB treatment, the current HDT development pipeline and translational research efforts for advancing further HDT options are presented. Ongoing clinical trials of HDTs for TB treatment, the current HDT development pipeline and translational research efforts for advancing further HDT options are presented.5

show abstract

“…Treatment with the statin simvastatin (at a dose of 25 mg kg -1 ) was shown to accelerate bacillary clearance in the lungs of mice when administered in combination with standard therapy 106 . However, a large retrospective analysis using a national medical claims database found that statins did not protect against tuberculosis in individuals with diabetes mellitus 107 . Some statins, such as rosuva statin, are not metabolized by CYP3A4 and are therefore unlikely to require dose adjustment due to rifampicin.…”

Section: Other Pde Inhibitorsmentioning

confidence: 99%

Advancing host-directed therapy for tuberculosis

2015

View full text Add to dashboard Cite

Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.

show abstract

The effects of statin use on the development of tuberculosis among patients with diabetes mellitus

Abstract: TB development among newly diagnosed type 2 DM was considerable, and statin use among these diabetics was not associated with a protective effect on TB incidence.

Cited by 36 publications

References 23 publications

Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort

Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

Advancing host-directed therapy for tuberculosis

Contact Info

Product

Resources

About